Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptideT-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Immunotherapy for metastatic melanoma.Combination strategies to enhance antitumor ADCC.Immunocytokines: a review of molecules in clinical development for cancer therapy.Novel antibody-based proteins for cancer immunotherapy.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesisEmerging classes of armed antibody therapeutics against cancerImmunocytokines
P2860
Q28066935-F77CB500-A678-40EC-BF30-A448C9DDC950Q33811204-32746092-EE5C-4EC9-846F-D729A5CBF117Q34548847-5129989D-47AD-40BE-9FC0-4B1780D68A5BQ35580479-49EBC002-26D5-49F4-B0C7-B108DE46233DQ36179663-CF05C8C2-BDEA-497D-9D37-3BA7BDC80CF3Q36550855-FCDFD9DF-0805-48FB-9429-C06AE1309F45Q36552580-FFA65639-CB4F-40D5-9AAD-BA39FA760B2EQ37038652-E680EAB1-9F19-4A69-9967-15B001B3FF47Q37485709-9D071349-40DF-4091-A197-5132BCD0656CQ37801939-9A65AA1B-7694-4828-BFCB-9B85AC6A1086Q37946772-FEE76A82-2446-42E8-96E6-1FB7F008660BQ38014085-504F9207-41AA-4474-8511-15D899C3D335Q38132742-84BBE492-43B9-4F58-8D6F-37676AEB3BC2Q38161370-5C72A611-509F-41D5-947F-1B0D6BA4F6B3Q38916529-8063DD47-3D4C-4D70-A24B-AE52B3F980BBQ50544077-22752E1D-F9E0-41C6-8BF2-3CC5D0975605Q56888932-4EA1D216-5A16-4E74-B78F-41E68D711AF0Q57911948-63ADD150-6E50-4945-9C52-E1EE8D4C268AQ57911975-EC161F97-7E7F-4C1A-9E44-C89516675496
P2860
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I/II open-label study of ...... metastatic malignant melanoma.
@en
Phase I/II open-label study of ...... in-2 immunocytokine EMD 273063
@nl
type
label
Phase I/II open-label study of ...... metastatic malignant melanoma.
@en
Phase I/II open-label study of ...... in-2 immunocytokine EMD 273063
@nl
prefLabel
Phase I/II open-label study of ...... metastatic malignant melanoma.
@en
Phase I/II open-label study of ...... in-2 immunocytokine EMD 273063
@nl
P2093
P2860
P356
P1476
Phase I/II open-label study of ...... metastatic malignant melanoma.
@en
P2093
Andreas Kovar
Antoni Ribas
John M Kirkwood
Michael A Morse
Michael B Atkins
Oscar Kashala
Stephen D Gillies
Theresa L Whiteside
William Gooding
P2860
P2888
P356
10.1186/1479-5876-7-68
P577
2009-07-29T00:00:00Z
P5875
P6179
1048534051